Biotech Values

[jbog]

Asco,

Same Old, Same Old.

It seems there's a lot of bread but no meat this year.

Tarceva's saturn maintainence trial looks great from an HR basis but the median pfs advantage is about a week.

What's getting to be an habit, avastin again is showing little to no OS benefit in numerous trials. There are more CRC trials which again, show no survival benefit. Another breast trial (ribbon) showed no OS benefit.

Medarex/Bristol are showing their mela drug has promise, but it's early.

ImmunoGen, Inc. didn't say a lot, but we know that their partner roche is already in phIII for Trastuzumab-DM1.